ATXN2 and autosomal dominant cerebellar ataxia: To demonstrate target engagement in future trials that aim at silencing SCA disease genes, the availability of sensitive immunoassays to measure the concentration of polyQ-expanded disease proteins like ATXN2 in body fluids is mandatory [76].